BioSpace News Archive

BD, a leading global medical technology company, reported quarterly revenues of $4.9 billion for the second fiscal quarter ended March 31, 2021.

Vizgen releases new dataset generated by Vizgen’s MERSCOPE™ which includes a high-resolution spatial map of GPCR and RTK expression within the mouse brain

Patient Wounds Documented by MolecuLight i:X Device Now Integrated with EHR Systems Through Net Health’s Tissue Analytics Platform

CENTOGENE’s rare disease mutation database offers new features and previously unpublished variants

The Company’s financial statements are prepared in accordance with accounting principles generally accepted in the United States.

EMPhASIS Cohort 2 Interim Analysis Confirmed 30 mg Dose of IMU-838 as Most Appropriate for Planned Phase 3 Program in Relapsing-Remitting Multiple Sclerosis, Expected to Begin in the Second Half of 2021

Epizyme, a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, provided business and portfolio updates and reported first quarter 2021 financial results.

Applications Based on Progression-Free Survival, Overall Survival, and Objective Response Rate Data From Respective Pivotal Phase 3 Trials

Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced Christopher J. Morabito, M.D. has been appointed Chief Medical Officer, effective May 10, 2021. Dr. Morabito will oversee the development of Fulcrum’s lead programs in facioscapulohumeral dystrophy (FSHD) and select hemoglobinopathies,

Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced its operational and financial results for the quarter ended March 31, 2021.